CERo Therapeutics Holdings, Inc.
CERO
$5.40
-$0.10-1.82%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 10.29M | 10.05M | 10.73M | 9.62M | 7.25M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.04M | 16.75M | 16.20M | 15.22M | 12.36M |
| Operating Income | -17.04M | -16.75M | -16.20M | -15.22M | -12.36M |
| Income Before Tax | -14.08M | -11.11M | -8.30M | -10.24M | -7.36M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -14.08 | -11.11 | -8.30 | -10.24 | -7.36 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.08M | -11.11M | -8.30M | -10.24M | -7.36M |
| EBIT | -17.04M | -16.75M | -16.20M | -15.22M | -12.36M |
| EBITDA | -16.68M | -16.35M | -15.76M | -14.77M | -11.90M |
| EPS Basic | -309.56 | -311.64 | -342.01 | -306.30 | -153.81 |
| Normalized Basic EPS | -166.37 | -159.43 | -182.20 | -154.03 | -42.32 |
| EPS Diluted | -309.56 | -311.64 | -342.01 | -306.30 | -153.81 |
| Normalized Diluted EPS | -166.37 | -159.43 | -182.20 | -154.03 | -42.32 |
| Average Basic Shares Outstanding | 5.91M | 5.43M | 1.86M | 559.50K | 37.90K |
| Average Diluted Shares Outstanding | 5.91M | 5.46M | 1.90M | 597.40K | 296.60K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |